PhotoCure ASA (PHO.OL)

55.30 -1.40 (-2.47%) At close: 04:25PM CEST

PhotoCure ASA

Hoffsveien 4
Oslo 0275
Norway
47 22 06 22 10
https://www.photocure.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Daniel Schneider	President & CEO	N/A	N/A	N/A
Mr. Erik Dahl	Chief Financial Officer	N/A	N/A	1957
Mr. David Moskowitz	Head of Investor Relations	N/A	N/A	N/A
Dr. Anders Neijber M.D.	Chief Medical Officer of Global Medical Affairs, Clinical Development and R&D	N/A	N/A	N/A
Mr. Tolv Hillestad	Group Controller	N/A	N/A	N/A

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in NOK.

Description

Photocure ASA, a specialty pharmaceutical company, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries, Germany, France, Austria, the United Kingdom, the BeNeLux, Italy, other European Countries, Canada, and the United States. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus infection and precancerous lesions of the cervix. The company sells its products to pharmaceutical wholesalers, pharmacies, and hospitals through license partners. Photocure ASA was founded in 1993 and is headquartered in Oslo, Norway.

Corporate governance

PhotoCure ASA’s ISS governance QualityScore as of 29 April 2024 is 7. The pillar scores are Audit: 1; Board: 6; Shareholder rights: 1; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.